Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vesicular glutamate transporter 2 (VGLUT2) is a membrane protein belonging to the solute carrier family 17, encoded by the SLC17A6 gene. It is primarily expressed in neuronal synaptic vesicles where it mediates the storage of glutamate, the major excitatory neurotransmitter, by transporting cytosolic glutamate into vesicles in preparation for synaptic release. VGLUT2 relies on the membrane potential (ΔΨ) and requires allosteric activation by protons (H⁺) and chloride ions (Cl⁻). It also exhibits a Cl⁻-conductance mechanism and, in certain contexts, can mediate Na⁺-dependent inorganic phosphate uptake, although its primary function is related to glutamate transport. Dysfunction or altered regulation of VGLUT2 is implicated in numerous CNS disorders characterized by abnormal excitatory neurotransmission, including epilepsy, schizophrenia, neurodegenerative diseases, and pain syndromes.
For inhibitors: Block VGLUT2-mediated vesicular glutamate uptake, decreasing synaptic glutamate release and excitatory neurotransmission
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vesicular glutamate transporter 2 (VGLUT2).